2021 COMPUTEX Forum Day 2: Unlocking Next-Generation Technologies
4.6.2021 13:03:00 EEST | Business Wire | Press release
The second day of COMPUTEX Forum, organized by TAITRA, featured "Critical Technology" and "Tomorrow Tech." World-renown tech leaders such as Qualcomm, QCT, WIN Semiconductors Corp., Siemens, Far EasTone Telecom, NVIDIA, and IBM shared their perspectives on the latest development of 5G, AI & IoT, and quantum computing, as well as their strategies for navigating in the new normal.
Cynthia Kiang, Director General of the Bureau of Foreign Trade, MOEA, Taiwan, said in her opening remarks that the recent global chip shortage underscores the importance of supply chain resilience, and that international cooperation is the best way to ensure supply chain efficiency and stability. She expects COMPUTEX to be a platform that helps with integrating global resources, allowing ecosystem partners to explore future business opportunities.
Qualcomm: Empowering the future of PC with mobile computing
With the onset of the pandemic and shift to remote working and learning, the way people use PCs has rapidly expanded. Alex Katouzian, Senior Vice President and General Manager of Mobile, Compute, and Infrastructure for Qualcomm Technologies, shared his unique perspectives on how 5G along with always connected PC are facilitating connectivity, mobility, and productivity as PC becomes the best collaborative tool in a mobile office. Qualcomm will also continue to collaborate with its ecosystem partners to realize the future of always connected PC.
QCT: 5G New Era: Great Convergence, Broad Ecosystem, Golden Opportunity
Mike Yang, President of QCT, talks about the great convergence of IT and CT, and the many new entrants into the Telco ecosystem that are changing our daily lives. With them more and more service providers will push for digital transformation and build 5G networks that will open up new opportunities for everyone, including operators and enterprises.
WIN Semiconductors Corp: Shaping the future with compound semiconductors
Dr. Yu-Chi (YC) Wang, Vice Chairman of WIN Semiconductors Corp emphasized that compound semiconductors are essential in realizing a life style built on seamless connection, precise sensing, and efficiency power. In addition, future life will be based on ubiquitous AI access with 6G, super IoT, and AI. Compound semiconductor will play a pivotal role to advance that future.
Siemens: Industrial 5G, Grid Edge and Connected Mobility will accelerate smart economy development and drive industrial innovation and transformation
Taiwan is crucial in the global supply chain of ICT components with a comprehensive industrial value chain. Erdal Elver, President and CEO of Siemens Taiwan pointed out that Taiwan has a clear advantage in introducing 5G innovative applications in manufacturing and city infrastructure. Siemens’ world-leading technologies and success stories in Industrial 5G, Grid Edge and Connected Mobility will assist Taiwan in ushering in application innovation in a variety of fields, helping Taiwan move toward its vision of "Digital Nation, Smart Island."
Far EasTone Telecom: Enabling clinical intelligence through telemedicine with 5G, IoT, big data, and AI
Chee Ching, President of Far EasTone Telecom, discussed medical applications in the 5G era. Telemedicine supported by 5G is capable of diagnosing patients remotely through features such as high resolution, big bandwidth, low latency, and massive connectivity. Telemedicine will also be able to detect and prevent diseases using big data and AIoT, ushering a new era of smart medicine. Chee Ching also pointed out that long-term care will be the extended application field for telehealth. With Taiwan expected to become a super-aged society by 2026, Far EasTone Telecom views this not only as a business opportunity but also as a social responsibility.
NVIDIA: Empowering collaboration across shared virtual worlds by addressing 3D workflows
Richard Kerris, NVIDIA Head of Worldwide Developer Relations and General Manager of Omniverse, indicated that a distributed workforce has become the norm with the rise of hybrid work. Remote working, however, has deepened the challenges of 3D workflows. NVIDIA Omniverse, the revolutionary new platform for virtual collaboration and simulation, can empower individuals and companies across multiple industries to address the challenges of complex 3D workflows by connecting users, content creation tools, and enabling AI to be used across shared virtual worlds.
IBM: Quantum computing
Norishige Morimoto, Vice President of IBM Research and Development of Japan, stated that quantum computing has yet to overcome obstacles on hardware and application development before becoming available for all. Now, IBM is collaborating with industry and universities including NTU, focusing on finance, chemistry, material industries.
2021 COMPUTEX Forum and keynote speeches are all available for viewing on #COMPUTEXVirtual online platform and COMPUTEX YouTube channel from now.
For more information:
COMPUTEX : https://www.computextaipei.com.tw/
InnoVEX : https://www.innovex.com.tw/
About COMPUTEX
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX,Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnovexVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
Explore #COMPUTEXVirtual now at https://virtual.computextaipei.com.tw/.
About TAITRA
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005260/en/
Contact information
Press:
Ms. Tessa Lin <tessalin@taitra.org.tw>
Ms. Li Chao < lichao@taitra.org.tw>
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
